AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
前日終値
$286.2
+$2.66 · +0.94%
日中の時刻はETです。市場データは遅延する場合があります。
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
日中レンジ
現在 $286.2
52週レンジ
現在 $286.2
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
18
著しい割高
センチメント
70
強気
リスク
19
低リスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
日中レンジ
現在 $286.2
52週レンジ
現在 $286.2
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 611.6億 USD | 563.34億 USD | 543.18億 USD | 580.54億 USD | 561.97億 USD |
| 売上原価 | 182.04億 USD | 169.04億 USD | 204.15億 USD | 174.14億 USD | 174.46億 USD |
| 粗利益 | 429.56億 USD | 394.3億 USD | 339.03億 USD | 406.4億 USD | 387.51億 USD |
| 研究開発 | 90.96億 USD | 127.91億 USD | 76.75億 USD | 65.1億 USD | 80.46億 USD |
| 販売・一般管理 | 140.1億 USD | 147.52億 USD | 128.72億 USD | 152.6億 USD | 123.49億 USD |
| 営業費用 | 278.81億 USD | 302.93億 USD | 211.46億 USD | 225.23億 USD | 208.27億 USD |
| 受取利息 | 2.66億 USD | 6.48億 USD | 5.4億 USD | 1.86億 USD | 3900万 USD |
| 支払利息 | 28.93億 USD | 28.08億 USD | 22.24億 USD | 22.3億 USD | 24.23億 USD |
| 減価償却費と償却費 | 81.39億 USD | 83.86億 USD | 86.98億 USD | 84.67億 USD | 85.21億 USD |
| 営業利益 | 150.75億 USD | 91.37億 USD | 127.57億 USD | 181.17億 USD | 179.24億 USD |
| 純利益 | 42.26億 USD | 42.78億 USD | 48.63億 USD | 118.36億 USD | 115.42億 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$316.87
上昇余地(10.72%)分割調整後の1株当たりの年間現金分配金。
$6.56
2025年(通年)+26.2% 以来 2021
2026年(一部):$6.92
$5.20
2,021
$5.64
2,022
$5.92
2,023
$6.20
2,024
$6.56
2,025
$6.92
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当予定 | 2027年1月15日 | $1.82Quarterly | 2027年1月15日 | 2027年2月16日 |
配当 | 2026年10月15日 | $1.73Quarterly | 2026年10月15日 | 2026年11月16日 |
配当 | 2026年7月15日 | $1.73Quarterly | 2026年7月15日 | 2026年8月14日 |
配当 | 2026年4月15日 | $1.73Quarterly | 2026年4月15日 | 2026年5月15日 |
配当 | 2026年1月16日 | $1.73Quarterly | 2026年1月16日 | 2026年2月17日 |
配当 | 2025年10月15日 | $1.64Quarterly | 2025年10月15日 | 2025年11月14日 |
配当落ち 2027年1月15日
$1.82
Quarterly
2027年1月15日基準 · 支払日 2027年2月16日
配当落ち 2026年10月15日
$1.73
Quarterly
2026年10月15日基準 · 支払日 2026年11月16日
配当落ち 2026年7月15日
$1.73
Quarterly
2026年7月15日基準 · 支払日 2026年8月14日
配当落ち 2026年4月15日
$1.73
Quarterly
2026年4月15日基準 · 支払日 2026年5月15日
配当落ち 2026年1月16日
$1.73
Quarterly
2026年1月16日基準 · 支払日 2026年2月17日
配当落ち 2025年10月15日
$1.64
Quarterly
2025年10月15日基準 · 支払日 2025年11月14日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T9675.43億0.81%119.93兆 JPY0.09%¥113,700-3.19%
Vanguard S&P 500 ETFVOO138.48億0.80%1兆 USD0.03%$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI130.58億0.72%6893億 USD0.03%$340.02-3.52%
iShares Core S&P 500 ETFIVV68.05億0.85%8034.1億 USD0.03%$693.71-3.52%
State Street SPDR S&P 500 ETFSPY61.02億0.81%7563.79億 USD0.09%$689.81-3.64%
Vanguard Morningstar Value ETFVTV50.09億1.87%1959億 USD0.03%$214.22-1.62%
State Street Health Care Select Sector SPDR ETFXLV36.55億7.79%469.2億 USD0.08%$177.24-0.12%
Vanguard Dividend Appreciation ETFVIG29.53億2.17%1158億 USD0.04%$235.69-1.87%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Dividend Appreciation ETFVIGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。